In a report that was submitted to the SEC, it was reported that the EVP/Chief Retail Officer of Qnb Corp Dale Westwood, an insider in question, made a stock market purchase for 218 shares of the stock exchange listed company, valued at near $7,978 U.S Dollars using an average price-per-share of $36.6 U.S Dollars. Dale Westwood today has rights to 7,590 shares which are around 0.22% of the Pennsylvania-based company’s market capitalization (total value of the shares outstanding).
Sphera Funds Management Ltd increased Neurocrine Biosciences Inc (NBIX) stake by 40.32% reported in 2017Q3 SEC filing. Sphera Funds Management Ltd acquired 25,000 shares as Neurocrine Biosciences Inc (NBIX)’s stock rose 19.84%. The Sphera Funds Management Ltd holds 87,000 shares with $5.33 million value, up from 62,000 last quarter. Neurocrine Biosciences Inc now has $6.89 billion valuation. The stock decreased 4.80% or $3.92 during the last trading session, reaching $77.81. About 1.69M shares traded or 79.53% up from the average. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 12.51% since January 9, 2017 and is uptrending. It has underperformed by 4.19% the S&P500.
Among 12 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 12 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci has $139.0 highest and $58.0 lowest target. $82’s average target is 5.38% above currents $77.81 stock price. Neurocrine Biosci had 39 analyst reports since August 18, 2015 according to SRatingsIntel. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Buy” rating by H.C. Wainwright on Thursday, November 2. BMO Capital Markets maintained the stock with “Buy” rating in Thursday, August 3 report. Oppenheimer maintained the stock with “Buy” rating in Friday, August 4 report. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Overweight” rating given on Thursday, October 8 by Piper Jaffray. Leerink Swann maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Monday, October 12 with “Outperform” rating. The stock has “Buy” rating by Piper Jaffray on Thursday, August 24. Oppenheimer maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating on Tuesday, December 12. Oppenheimer has “Buy” rating and $85.0 target. The firm has “Buy” rating by H.C. Wainwright given on Friday, August 4. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Buy” rating by Jefferies on Tuesday, August 18. The firm has “Buy” rating by Cowen & Co given on Friday, October 27.
Since August 4, 2017, it had 0 buys, and 11 sales for $10.34 million activity. Shares for $3.04M were sold by OBrien Christopher Flint on Tuesday, September 5. $6,000 worth of stock was sold by Lippoldt Darin on Wednesday, September 6. Bozigian Haig P. also sold $1.13M worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Friday, August 4. 18,084 shares were sold by Lloyd-Smith Malcolm, worth $1.40 million on Tuesday, January 2. Shares for $276,420 were sold by Gano Kyle. Grigoriadis Dimitri E. had sold 15,354 shares worth $844,470.
Investors sentiment increased to 1.66 in Q3 2017. Its up 0.41, from 1.25 in 2017Q2. It increased, as 22 investors sold NBIX shares while 45 reduced holdings. 32 funds opened positions while 79 raised stakes. 92.69 million shares or 0.83% more from 91.92 million shares in 2017Q2 were reported. Thrivent Financial For Lutherans holds 0.05% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 252,593 shares. Federated Pa reported 124,654 shares or 0.02% of all its holdings. Pub Employees Retirement System Of Ohio invested 0.01% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Moreover, State Board Of Administration Of Florida Retirement has 0.02% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 120,426 shares. Profund Advisors Limited Liability Corporation accumulated 36,491 shares. Sei Invs stated it has 117,710 shares or 0.03% of all its holdings. 2.46M are held by State Street. Point72 Asset Management LP invested in 0.08% or 276,322 shares. Bb Biotech Ag reported 5.87% stake. The New York-based Jennison Assocs Limited Liability Company has invested 0.02% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Balyasny Asset Management Limited Liability Corporation holds 0.14% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 602,682 shares. Tekla Mgmt Limited Co accumulated 562,467 shares. Great West Life Assurance Com Can has invested 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Davidson Kempner Cap Mngmt LP invested in 0.22% or 119,300 shares. Cubist Systematic Strategies Lc reported 1,736 shares or 0.01% of all its holdings.
Sphera Funds Management Ltd decreased Syndax Pharmaceuticals Inc stake by 47,838 shares to 248,472 valued at $2.91M in 2017Q3. It also reduced Teva Pharmaceutical Fin Llc stake by 2,650 shares and now owns 11,885 shares. Dova Pharmaceuticals Inc was reduced too.
Since January 3, 2018, it had 1 insider purchase, and 0 selling transactions for $7,978 activity. Westwood Dale A bought $7,978 worth of stock.
The stock increased 0.21% or $0.095 during the last trading session, reaching $44.895. About shares traded. QNB Corp. (OTCMKTS:QNBC) has 0.00% since January 9, 2017 and is . It has underperformed by 16.70% the S&P500.
Investors sentiment Infinity in 2017 Q3. Its in 2017Q2. It , as 0 investors sold QNB Corp. shares while 0 reduced holdings. 0 funds opened positions while 2 raised stakes. 598,808 shares or 2.96% more from 581,608 shares in 2017Q2 were reported. Maltese Cap has 75,100 shares. Vantage Invest Lc holds 0% in QNB Corp. (OTCMKTS:QNBC) or 100 shares. Philadelphia Tru Com accumulated 0.03% or 9,620 shares. Banc Funds Ltd Liability Co holds 214,584 shares or 0.39% of its portfolio.